NovoCure Limited (NVCR)
NVCRNASDAQ-GSMedical/Dental Instruments
$11.83
+0.1100 (+0.94%) today
Closed, Nov 13, 4:00 PM ET
- Market cap
- $1.38bn
- P/E
- –
- EPS, last 4 quarters
- $-1.06
- Dividend yield
- –
- Day range
- –
- 52-week range
- $9.82 to $21.45
- Average volume
- –
- Previous close
- $11.72
Analysts
3 coveringHold2 buy, 1 hold, 0 sell
Targets a year out average $23.75, +100.8% from here
Earnings
next estimate $-0.2300Next report
Dec 2025
+46.3%
Mar 2026
-55.0%
Jun 2026
+56.7%
Sep 2026
+57.1%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $174.35m | $174.06m | $183.58m | $193.40m |
| Gross profit | $132.19m | $135.13m | $142.48m | $148.87m |
| Operating income | -$40.39m | -$67.42m | -$10.56m | -$6.17m |
| Net income | -$24.50m | -$71.14m | -$15.66m | -$10.44m |
Last four quarters: revenue $725.39m, margin -16.8%, free cash flow -$24.61m
News
8 latest- Weekly Buzz: LLY, JNJ Win FDA Nod; SION, NNOX, Cut Jobs; PFE, ARGX Strike Deals RTTNews · 21 hours ago
- FDA Rejects NovoCure’s Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.The Motley Fool · 4 days ago
- NovoCure Limited Receives FDA Not Approvable Letter for Optune Mya® PMA ApplicationFintel · 5 days ago
- FDA Cites Uncertainty Over Clinical Benefit In Novocure's Optune Mya Application; Stock Down RTTNews · 5 days ago
- Novocure Receives FDA Not Approvable Letter For Optune Mya In Brain Metastases; Stock Down RTTNews · 5 days ago
- Don't Overlook NovoCure (NVCR) International Revenue Trends While Assessing the StockZacks · Nov 2, 2026
- NovoCure: 3 Key Takeaways for Long-Term InvestorsThe Motley Fool · Nov 1, 2026
- NovoCure Q3 Earnings Call HighlightsMarketBeat · Oct 29, 2026
The company
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, pancreatic cancer, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Novocure has several additional ongoing or completed clinical trials exploring the use of Tumor Treating Fields therapy in the treatment of glioblastoma, non-small cell lung cancer and pancreatic cancer.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Exchange
- NASDAQ-GS
- Region
- Europe
- Website
- novocure.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.